DHR Danaher

Danaher Corp. operates as a medical company, which designs, manufactures, and markets professional, medical, industrial and commercial products and services. It operates through the following segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines. The Diagnostics segment comprises of analytical instruments, reagents, consumables, software, and services that hospitals, physician's offices, reference laboratories, and other critical care settings use to diagnose disease and make treatment decisions. The Environmental & Applied Solution segment offers products and services that help protect important resources and keep global food and water supplies safe. The company was founded by Steven M. Rales and Mitchell P. Rales in 1969 and is headquartered in Washington, DC.
Company profile
Ticker
DHR, DHR+A, DHR+B
Exchange
Website
CEO
H. Lawrence Culp
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Fortive • Roper • Ametek • Sensata Technologies Holding • Keysight • MKS Instruments • Cognex • Rudolph • Hurco Companies • Sypris Solutions ...
Former names
DMG INC
SEC CIK
Corporate docs
IRS number
591995548
DHR stock data
()
News
Why Is It Moving? Analyzing The Upward Movement in Danaher's Stock Today
13 Apr 21
'Halftime Report' Final Trades: Danaher, Nautilus And More
24 Mar 21
Danaher Says Co's Beckman Coulter SARS-CoV-2 IgG II Antibody Test Receives Emergency Use Authorization From FDA
23 Mar 21
Benzinga's Top Ratings Upgrades, Downgrades For March 3, 2021
3 Mar 21
Barclays Initiates Coverage On Danaher with Overweight Rating, Announces Price Target of $260
3 Mar 21
Press releases
Danaher Provides Update On First Quarter 2021 Financial Performance
13 Apr 21
Danaher Schedules First Quarter 2021 Earnings Conference Call
25 Mar 21
Beckman Coulter's SARS-CoV-2 IgG II antibody test receives Emergency Use Authorization from the FDA
23 Mar 21
Beckman Coulter Offers $4/High-throughput Antigen Test to Support U.S. Government Initiative to Expand COVID-19 Testing
18 Mar 21
IDT Acquires Swift Biosciences, a Pioneer in the Development of Next-Generation Sequencing (NGS) Library Preparation Genomics Kits for Academic, Translational, and Clinical Research
11 Mar 21
Investment data
Securities sold
Number of investors
Calendar
24 Feb 21
21 Apr 21
31 Dec 21
Financial summary
Quarter (USD) |
Dec 20 | Oct 20 | Jul 20 | Apr 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) |
Dec 20 | Dec 19 | Dec 18 | Dec 17 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Financial data from Danaher earnings reports.
Cash burn rate (estimated) | Burn method: Change in cash | Burn method: Operating income/loss | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 6.04B | 6.04B | 6.04B | 6.04B | 6.04B | 6.04B |
Cash burn (monthly) | (positive/no burn) | 1.16B | (positive/no burn) | (positive/no burn) | (positive/no burn) | (positive/no burn) |
Cash used (since last report) | n/a | 4.28B | n/a | n/a | n/a | n/a |
Cash remaining | n/a | 1.75B | n/a | n/a | n/a | n/a |
Runway (months of cash) | n/a | 1.5 | n/a | n/a | n/a | n/a |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
26 Feb 21 | Mitchell P Rales | Common Stock, par value $.01 | Buy | Aquire P | Yes | No | 221.46 | 900 | 199.31K | 3,156 |
26 Feb 21 | Mitchell P Rales | Common Stock, par value $.01 | Buy | Aquire P | Yes | No | 221.46 | 900 | 199.31K | 3,156 |
26 Feb 21 | Mitchell P Rales | Common Stock, par value $.01 | Buy | Aquire P | No | No | 221.59 | 4,800 | 1.06M | 2,409,190 |
24 Feb 21 | Gutierrez-Ramos Jose-Carlos | Common Stock | Grant | Aquire A | No | No | 223 | 2,545 | 567.54K | 2,545 |
24 Feb 21 | Gutierrez-Ramos Jose-Carlos | Employee Stock Option Common Stock | Grant | Aquire A | No | No | 223 | 13,190 | 2.94M | 13,190 |
24 Feb 21 | Lalor Angela S | Common Stock | Payment of exercise | Dispose F | No | No | 223 | 2,539 | 566.2K | 34,839 |
24 Feb 21 | Lalor Angela S | Employee Stock Option Common Stock | Grant | Aquire A | No | No | 223 | 18,800 | 4.19M | 18,800 |
24 Feb 21 | King William | Common Stock | Payment of exercise | Dispose F | No | No | 223 | 1,671 | 372.63K | 24,417 |
24 Feb 21 | King William | Employee Stock Option Common Stock | Grant | Aquire A | No | No | 223 | 14,510 | 3.24M | 14,510 |
24 Feb 21 | Jennifer Honeycutt | Common Stock | Payment of exercise | Dispose F | No | No | 223 | 835 | 186.21K | 8,098 |
Institutional ownership Q4 2020
Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.
78.3% owned by funds/institutions
13F holders |
Current |
---|---|
Total holders | 1729 |
Opened positions | 224 |
Closed positions | 86 |
Increased positions | 594 |
Reduced positions | 691 |
13F shares |
Current |
---|---|
Total value | 123.97B |
Total shares | 558.01M |
Total puts | 2.22M |
Total calls | 2.4M |
Total put/call ratio | 0.9 |
Largest owners |
Shares | Value |
---|---|---|
Vanguard | 48.74M | $10.83B |
BLK Blackrock | 45.71M | $10.15B |
TROW T. Rowe Price | 31.36M | $6.96B |
FMR | 31.14M | $6.92B |
STT State Street | 25.39M | $5.64B |
Wellington Management | 21.24M | $4.72B |
Massachusetts Financial Services | 14.35M | $3.19B |
MS Morgan Stanley | 13.65M | $3.03B |
BAC Bank Of America | 11.82M | $2.63B |
Geode Capital Management | 9.69M | $2.15B |
Financial report summary
?Competition
Bio-Rad Laboratories • Dover • Parker-Hannifin • Quidel • Accelerate Diagnostics • Meridian Bioscience • Hologic • Esco • Waters • LuminexRisks
- The COVID-19 pandemic has adversely impacted, and continues to pose risks to, certain elements of our business and our financial statements, the nature and extent of which are highly uncertain and unpredictable.
- We face intense competition and if we are unable to compete effectively, we may experience decreased demand and decreased market share. Even if we compete effectively, we may be required to reduce the prices we charge.
- Our growth depends in part on the timely development and commercialization, and customer acceptance, of new and enhanced products and services based on technological innovation.
- The health care industry and related industries that we serve have undergone, and are in the process of undergoing, significant changes in an effort to reduce (and increase the predictability of) costs, which can adversely affect our business and financial statements.
- International economic, political, legal, compliance, social and business factors can negatively affect our business and financial statements.
- Our growth can suffer if the markets into which we sell our products and services decline, do not grow as anticipated or experience cyclicality.
- Certain of our businesses rely on relationships with collaborative partners and other third-parties for development, supply and marketing of certain products, potential products and technologies, and such collaborative partners or other third-parties could fail to perform sufficiently.
- Any inability to consummate acquisitions at our historical rate and at appropriate prices, and to make appropriate investments that support our long-term strategy, could negatively impact our growth rate and stock price.
- Our acquisition of businesses, investments, joint ventures and other strategic relationships could negatively impact our business and financial statements.
- The indemnification provisions of acquisition agreements by which we have acquired companies may not fully protect us and as a result we may face unexpected liabilities.
- Divestitures or other dispositions could negatively impact our business, and contingent liabilities from businesses that we or our predecessors have disposed could adversely affect our business and financial statements.
- Potential indemnification liabilities pursuant to the Communications Disposition, the Fortive Disposition or the Envista Disposition could materially and adversely affect our business and financial statements.
- We could incur significant liability if any of the Communications Disposition, the Fortive Disposition or the Envista Disposition is determined to be a taxable transaction.
- A significant disruption in, or breach in security of, our information technology systems or data or violation of data privacy laws can adversely affect our business and financial statements.
- Defects and unanticipated use or inadequate disclosure with respect to our products or services, or allegations thereof, can adversely affect our business and financial statements.
- If we suffer loss to our facilities, supply chains, distribution systems or information technology systems due to catastrophe or other events, our operations could be seriously harmed.
- The manufacture of many of our products is a highly exacting and complex process, and if we directly or indirectly encounter problems manufacturing products, our business and financial statements could suffer.
- If we cannot adjust our manufacturing capacity or the purchases required for our manufacturing activities to reflect changes in market conditions and customer demand, our business and financial statements may suffer. In addition, our reliance upon sole or limited sources of supply for certain materials, components and services can cause production interruptions, delays and inefficiencies.
- Adverse changes in our relationships with, or the financial condition, performance, purchasing patterns or inventory levels of, key distributors and other channel partners can adversely affect our business and financial statements.
- Our financial results are subject to fluctuations in the cost and availability of commodities that we use in our operations.
- Our restructuring actions can have long-term adverse effects on our business and financial statements.
- Work stoppages, union and works council campaigns and other labor disputes could adversely impact our productivity and results of operations.
- If we are unable to adequately protect our intellectual property, or if third-parties infringe our intellectual property rights, we may suffer competitive injury or expend significant resources enforcing our rights. These risks are particularly pronounced in countries in which we do business that do not have levels of protection of intellectual property comparable to the United States.
- Third-parties from time to time claim that we are infringing or misappropriating their intellectual property rights and we could suffer significant litigation expenses, losses or licensing expenses or be prevented from selling products or services.
- The U.S. government has certain rights to use and disclose some of the intellectual property that we license and could exclusively license it to a third-party if we fail to achieve practical application of the intellectual property.
- Our outstanding debt has increased significantly as a result of the Cytiva Acquisition, and we may incur additional debt in the future. Our existing and future indebtedness may limit our operations and our use of our cash flow and negatively impact our credit ratings; and any failure to comply with the covenants that apply to our indebtedness could adversely affect our business and financial statements.
- We may be required to recognize impairment charges for our goodwill and other intangible assets.
- Foreign currency exchange rates can adversely affect our financial statements.
- Changes in our tax rates or exposure to additional income tax liabilities or assessments can affect our profitability. In addition, audits by tax authorities can result in additional tax payments for prior periods.
- Changes in tax law relating to multinational corporations could adversely affect our tax position.
- Legal, political, and economic uncertainty surrounding the exit of the United Kingdom (“UK”) from the EU could have an adverse effect on our business and financial statements.
- Our defined benefit pension plans are subject to financial market risks that could adversely affect our financial statements.
- Significant developments or changes in U.S. laws or policies, including changes in U.S. trade policies and tariffs and the reaction of other countries thereto, particularly China, can have an adverse effect on our business and financial statements.
- Our business and financial statements can be impaired by improper conduct by any of our employees, agents or business partners.
- Our businesses are subject to extensive regulation; failure to comply with those regulations could adversely affect our business and financial statements.
- We are subject to or otherwise responsible for a variety of litigation and other legal and regulatory proceedings in the course of our business that can adversely affect our business and financial statements.
- Certain of our businesses are subject to extensive regulation by the U.S. FDA and by comparable agencies of other countries, as well as laws regulating fraud and abuse in the healthcare industry and the privacy and security of health information. Failure to comply with those regulations could adversely affect our business and financial statements.
- Our products are subject to clinical trials, the results of which may be unexpected, or perceived as unfavorable by the market, and could adversely affect our business and financial statements.
- Off-label marketing of our products could result in substantial penalties.
- Certain modifications to our products may require new 510(k) clearances or other marketing authorizations and may require us to recall or cease marketing our products.
- Our operations, products and services expose us to the risk of environmental, health and safety liabilities, costs and violations that could adversely affect our business and financial statements.
- Changes in governmental regulations can reduce demand for our products or services or increase our expenses.
Management Discussion
- Total sales increased 24.5% on a year-over-year basis in 2020 primarily as a result of an increase in sales from acquired businesses, net of divestitures, primarily due to the acquisition of Cytiva, as well as an increase in core sales resulting from the factors discussed below by segment. The impact of currency translation did not have a significant impact on reported sales on a year-over-year basis in 2020 as the negative impact of a stronger U.S. dollar in the first half of 2020 was offset by the favorable impact of the weakening of the U.S. dollar in the second half of 2020.
Content analysis
?
Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. senior Bad
|
New words:
AbbVie, ABO, accessing, acquiree, aid, architecture, Asian, aspect, attack, BARDA, baseline, bioprocessing, Black, bore, broadening, built, candidate, capability, career, cent, certainty, childcare, CMS, coaching, confirm, contributor, cooperation, culture, curb, cybersecurity, daily, deeply, departure, deploying, deposit, depressed, descent, developmental, distancing, divestiture, division, DPA, EHS, elder, eldercare, enterprise, envisioned, evolve, evolved, evolving, explaining, felt, female, fill, filled, fuel, gender, guideline, healthy, hiring, home, Honeycutt, idea, Immune, incomplete, internationally, Jennifer, job, Latinx, launched, learning, LGBTQ, Listen, logo, macroeconomic, media, mental, mentoring, mentorship, misapplied, motivate, movement, nearest, negligible, obsolescence, optimize, orthe, outage, overcharged, PBO, people, permissible, philosophy, postponed, precautionary, premature, prevalence, primer, proactively, probe, profile, protectionism, proximity, race, ratified, recession, recruiting, recurrence, relaxed, reopening, Repertoire, resume, reward, rewarded, riot, rooted, royalty, Scientific, sequential, sequentially, shortage, situation, solution, stage, staggered, subside, subsided, supervisor, survey, surveyed, Synlogic, tailored, Talk, Team, temperature, therewith, thrive, toolkit, travel, tutoring, Underpinned, underrepresented, unprecedented, unsanctioned, upgrade, vaccine, waiting, wearing, Women
Removed:
aliquotting, called, challenge, characteristic, claimed, clarified, clarity, column, coverslipping, Delaware, disaggregate, discontinue, discontinuing, distributing, DMG, expired, feet, flat, Florida, Genetix, histology, Hong, insight, Italy, jointly, Joyce, Jr, judgmental, Kong, lessor, lost, master, MEDIABEACON, medium, Medtronic, membership, Mortgage, narrative, nonmonetary, obligated, page, progressively, ranking, reached, reader, referendum, reincorporated, renewing, reorganized, restorative, returned, revaluation, shortening, spectrum, square, stemming, sublet, subtotal, suitable, SURGIPATH, tariff, terminal, unchanged, unfulfilled, unusual, vacate, voted
Financial reports
10-K
2020 FY
Annual report
24 Feb 21
10-Q
2020 Q3
Quarterly report
21 Oct 20
10-Q
2020 Q2
Quarterly report
22 Jul 20
10-Q
2020 Q1
Quarterly report
6 May 20
10-K
2019 FY
Annual report
21 Feb 20
10-Q
2019 Q3
Quarterly report
23 Oct 19
10-Q
2019 Q2
Quarterly report
17 Jul 19
10-Q
2019 Q1
Quarterly report
17 Apr 19
10-K
2018 FY
Annual report
20 Feb 19
10-Q
2018 Q3
Quarterly report
17 Oct 18
Current reports
8-K
Danaher Provides Update on First Quarter 2021 Financial Performance
13 Apr 21
8-K
Danaher Reports Fourth Quarter and Full Year 2020 Results
27 Jan 21
8-K
Results of Operations and Financial Condition
13 Jan 21
8-K
Danaher Reports Third Quarter 2020 Results
21 Oct 20
8-K
Entry into a Material Definitive Agreement
6 Oct 20
8-K
Danaher Reports Second Quarter 2020 Results
23 Jul 20
8-K
Entry into a Material Definitive Agreement
10 Jun 20
8-K/A
Completion of Acquisition or Disposition of Assets
21 May 20
8-K
Material Modifications to Rights of Security Holders
12 May 20
8-K
Danaher Reports First Quarter 2020 Results
6 May 20
Registration and prospectus
S-3ASR
Automatic shelf registration
2 Apr 21
25-NSE
Exchange delisting
5 Nov 20
424B5
Prospectus supplement for primary offering
1 Oct 20
FWP
Free writing prospectus
29 Sep 20
424B5
Prospectus supplement for primary offering
29 Sep 20
8-A12B
Registration of securities on exchange
12 May 20
424B5
Prospectus supplement for primary offering
11 May 20
424B5
Prospectus supplement for primary offering
11 May 20
FWP
Free writing prospectus
8 May 20
424B5
Prospectus supplement for primary offering
7 May 20
Proxies
DEFA14A
Additional proxy soliciting materials
25 Mar 21
DEF 14A
Definitive proxy
25 Mar 21
DEFA14A
Additional proxy soliciting materials
17 Apr 20
DEFA14A
Additional proxy soliciting materials
25 Mar 20
DEF 14A
Definitive proxy
25 Mar 20
DEFA14A
Additional proxy soliciting materials
27 Mar 19
DEF 14A
Definitive proxy
27 Mar 19
DEF 14A
Definitive proxy
27 Mar 18
DEFA14A
Additional proxy soliciting materials
27 Mar 18
DEF 14A
Definitive proxy
30 Mar 17
Other
SD
Conflict minerals disclosure
22 May 20
SD
Conflict minerals disclosure
28 May 19
UPLOAD
Letter from SEC
22 May 19
CORRESP
Correspondence with SEC
20 May 19
UPLOAD
Letter from SEC
7 May 19
SD
Conflict minerals disclosure
21 May 18
SD
Conflict minerals disclosure
29 May 17
NO ACT
No action letter
18 Jan 17
NO ACT
No action letter
18 Dec 16
SD
Conflict minerals disclosure
25 May 16
Ownership
4
DANAHER / MITCHELL P RALES ownership change
2 Mar 21
4
DANAHER / Joakim Weidemanis ownership change
26 Feb 21
4
DANAHER / Daniel Raskas ownership change
26 Feb 21
4
DANAHER / Matthew McGrew ownership change
26 Feb 21
4
DANAHER / ROBERT S LUTZ ownership change
26 Feb 21
4
DANAHER / Angela S Lalor ownership change
26 Feb 21
4
DANAHER / William King ownership change
26 Feb 21
4
DANAHER / Jennifer Honeycutt ownership change
26 Feb 21
4
DANAHER / Brian W Ellis ownership change
26 Feb 21
4
DANAHER / Rainer Blair ownership change
26 Feb 21
Patents
GRANT
Utility
Charge electrode
13 Apr 21
There is provided a charge electrode for charging ink droplets for continuous ink jet printing.
APP
Utility
Apparatus for Fluid Line Management In a Bioprocessing System
8 Apr 21
In an embodiment, a tubing module for a bioprocessing system includes a first tubing holder block configured to receive at least one pump tube and hold the at least one pump tube in position for selective engagement with a peristaltic pump, a second tubing holder block configured to receive a plurality of pinch valve tubes and hold each pinch valve tube of the plurality of pinch valve tubes in position for selective engagement with a respective actuator of a pinch valve array, and wherein the first tubing holder block and the second tubing holder block are interconnected.
APP
Utility
Bioprocessing Apparatus
8 Apr 21
An apparatus for bioprocessing includes a housing, a drawer receivable within the housing, the drawer including a plurality of sidewalls and a bottom defining a processing chamber, and a generally open top, the drawer being movable between a closed position in which the drawer is received within the housing, and an open position in which the drawer extends from the housing enabling access to the processing chamber through the open top, and at least one bed plate positioned within the processing chamber and configured to receive a bioreactor vessel.
APP
Utility
Bioprocessing Vessel
8 Apr 21
A bioreactor vessel includes a bottom plate, a vessel body coupled to the bottom plate, the vessel body and the bottom plate defining an interior compartment therebetween, and a plurality of recesses formed in the bottom plate, each recess of the plurality of recesses being configured to receive a corresponding alignment pin on a bed plate for aligning the bioreactor vessel on the bed plate.
APP
Utility
Nucleic Acid Elution
8 Apr 21
This invention relates to the storage on a solid matrix of genetic material, in particular DNA that has been purified prior to the application to the solid matrix.
Transcripts
2020 Q3
Earnings call transcript
22 Oct 20
2020 Q2
Earnings call transcript
23 Jul 20
2020 Q1
Earnings call transcript
7 May 20
2019 Q4
Earnings call transcript
30 Jan 20
2019 Q3
Earnings call transcript
24 Oct 19
2019 Q2
Earnings call transcript
18 Jul 19
2019 Q1
Earnings call transcript
18 Apr 19
2018 Q4
Earnings call transcript
29 Jan 19
2018 Q3
Earnings call transcript
18 Oct 18
2018 Q2
Earnings call transcript
19 Jul 18
Reddit threads
Daily Discussion Thread - April 21st, 2021
21 Apr 21
Daily Discussion Thread - April 20th, 2021
20 Apr 21
Daily Discussion Thread - April 19th, 2021
19 Apr 21
What 'Under The Radar' Stock Have You Been Buying?
18 Apr 21
Best defensive stocks in a downturn? WMT JNJ?
18 Apr 21
5 Companies to set-and-forget hold for 10 years+
16 Apr 21
Daily General Discussion and spitballin thread - April 16, 2021
16 Apr 21
Safe stock or ETF plays
15 Apr 21
Daily Plays - April 07, 2021
7 Apr 21
Dividend Aristocrats vs S&P500
3 Apr 21